FDA approves Apellis’ therapy to treat two serious, rare kidney diseases
HQ Team July 30, 2025: The US Food and Drug Administration has approved Apellis Pharmaceuticals, Inc.’s medicine for treating two rare and serious
HQ Team July 30, 2025: The US Food and Drug Administration has approved Apellis Pharmaceuticals, Inc.’s medicine for treating two rare and serious
HQ Team July 29, 2025: Dementia patients are diagnosed on average 3.5 years after symptoms are first noticed, and it takes an even
HQ Team July 29, 2025: The US Food and Drug Administration cleared PTC Therapeutics’ sepiapterin for treating children and adults with a rare
HQ Team July 28, 2025: Britain’s GSK Plc will pay Jiangsu Hengrui Pharmaceuticals $500 million upfront to acquire global licensing rights for the
HQ Team July 28, 2025: At least 24 children under the age of five died of malnutrition this month in the conflict-ridden Gaza
HQ Team July 21, 2025: AstraZeneca Plc’s therapy for a certain type of advanced lung cancer, in combination with chemotherapy, helped patients live
HQ Team July 17, 2025: Artificial intelligence platforms for psychiatric patients are showing a pattern of racial bias by proposing different treatments for